A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects With Residual Measurable Disease

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The incidence of drug-related adverse events of grade 3 or higher during the induction period of Ipilimumab

Outcome Time Frame:

Up to Week 24

Safety Issue:

Yes

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

United States: Food and Drug Administration

Study ID:

CA184-201

NCT ID:

NCT01611558

Start Date:

August 2012

Completion Date:

March 2016

Related Keywords:

• Ovarian Cancer
• Ovarian Neoplasms